Skip to main content

Main menu

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • For authors
    • Instructions for authors
    • Submit a manuscript
    • Author FAQs
    • Open access
    • COVID-19 submission information
  • Alerts
  • Podcasts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • For authors
    • Instructions for authors
    • Submit a manuscript
    • Author FAQs
    • Open access
    • COVID-19 submission information
  • Alerts
  • Podcasts
  • Subscriptions

TB or not TB: update from the ERS Respiratory Infection Assembly 10

M. Miravitlles, G. Ferrara, C. Lange, G. Dimopoulos, G. Rohde, F. Blasi, G.B. Migliori
European Respiratory Journal 2010 36: 665-670; DOI: 10.1183/09031936.00054410
M. Miravitlles
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
G. Ferrara
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
C. Lange
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
G. Dimopoulos
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
G. Rohde
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
F. Blasi
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
G.B. Migliori
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: giovannibattista.migliori@fsm.it
  • Article
  • Info & Metrics
  • PDF
Loading

Abstract

Lower respiratory tract infections and tuberculosis represent some of the top health priorities in Europe. In the present report, the most recent advances in the field of disease control, clinical research and basic science of lower respiratory tract infections and tuberculosis are presented through analysis of some of the best abstracts presented at the 19th European Respiratory Society Congress in Vienna (Austria).

Pathogenesis, diagnosis, treatment, prognostic factors and novel diagnostic techniques relevant for bacterial and viral infections, as well as new tools for the diagnosis of latent and active tuberculosis in different sub-groups of patients, are discussed. The growing epidemiological threat represented by multidrug-resistant and extensively drug-resistant tuberculosis cases is presented and its impact analysed.

  • European Respiratory Society Congress
  • respiratory infections
  • tuberculosis

Lower respiratory tract infections (LRTIs) are common and associated with major morbidity, mortality and financial burden 1. Likewise, tuberculosis (TB) is confirmed to be a global emergency in terms of morbidity and mortality 2, 3. The cursed duet of TB/HIV continues to exert a dramatic epidemiological impact in settings with a high HIV prevalence (e.g. in sub-Saharan Africa, India, Russia and Latin America), with potential for further worsening when multidrug-resistant (MDR) and extensively drug-resistant (XDR) TB are present (e.g. in several countries of the former Soviet Union, representing the borders of Europe) 4.

Apart from the critical issue of political commitment and funding available in the southern part of the world, several key research questions remain open in the field of infection and disease control, clinical research and basic science.

The European Respiratory Society (ERS) Respiratory Infection Assembly (Assembly 10) actively supports several activities in the field of research, disease control and education, also being involved in projects funded by the European Union (e.g. the network of excellence Genomics to combat Resistance against Antibiotics in Community-acquired LRTI in Europe (GRACE) 5 and the Pan-European network for study and clinical management of drug resistant tuberculosis (TB PAN-NET) 6, belonging to the 6th and 7th Framework Programmes, respectively) and in the European Centre for Disease Prevention and Control (ECDC) through the involvement of the Tuberculosis Network (European Trials Group) (TBNET), which is an ERS clinical research collaboration 7.

The aim of the present article is to describe the main activities performed by the two Groups (10.1 and 10.2) composing Assembly 10 through the analysis of some of the best abstracts presented to the 19th ERS Congress in Vienna (Austria) by members of the Assembly.

RESPIRATORY INFECTIONS

The number of abstracts submitted to, and accepted by, the Respiratory Infections Group has been growing during recent years, from 171 abstracts accepted and presented in 2007 to 204 abstracts accepted in 2009, representing 75% of those submitted, and fairly similar to the 77% general acceptance rate. These abstracts have been distributed among three oral, three E-poster and six thematic poster sessions. These sessions covered the most important aspects of respiratory infections, from pathogenesis to diagnosis, treatment, prognostic factors and the description of novel diagnostic techniques that may represent an advance in the care of patients in the future.

The first oral session was dedicated to the respiratory infections caused by Pseudomonas aeruginosa. The definition of risk factors for P. aeruginosa infection is a potentially important issue. The antibiotic treatment is totally different compared to the treatments directed against common microorganisms, and the progression of the patients can be worse if antipseudomonal antibiotics are not given early enough 8. Jiang and Li 9 analysed the relationship between the formation of the biofilm and production of various β-lactamases and observed that the biofilm may exert different effects on the production of β-lactamases by P. aeruginosa depending upon the different genotypes. Various studies in the literature have identified some of the risk factors associated with P. aeruginosa infection in chronic obstructive pulmonary disease (COPD) 10–13. Impairment of lung function is the main risk factor for infection with this microorganism 10, 11. Overall, the rate of P. aeruginosa infection is ∼10–15% in series of patients with COPD exacerbations with a forced expiratory volume in 1 s of <50% requiring hospitalisation, and this proportion is increased in patients admitted to the intensive care unit needing mechanical ventilation 8, 14. However, the issue of P. aeruginosa in COPD exacerbations is far from being clear. A recent study has demonstrated that there are different P. aeruginosa carriage patterns in patients with COPD, and that mucoid strains are uncommon but persistent 15. Regarding treatment of P. aeruginosa infection, O'Donnell et al. 16 reported the design of a phase-II randomised study of liposomal amikacin for inhalation nebulised once daily in patients with bronchiectasis and chronic P. aeruginosa infection. At the time of submission, only results regarding safety were available, and no efficacy data were provided. In contrast, Bilton et al. 17 reported the results of their trial of inhaled liposomal ciprofloxacin hydrochloride in patients with noncystic fibrosis bronchiectasis. They reported that both the 3-mL (150 mg) and 6-mL (300 mg) doses of the drug demonstrated significant mean decreases against baseline in P. aeruginosa colony-forming units over the 28-day treatment period of 3.5 log (p<0.001) and 4.0 log units (p<0.001), and the treatment was well tolerated. Treatment of bronchial infection with the newly formulated antibiotics by inhalation opens a new perspective that may be useful in a broad range of patients, from cystic fibrosis to bronchiectasis, severe COPD with bronchiectasis and frequent infective exacerbations. New studies in well-defined populations are required.

The second oral session included abstracts dealing with the impact of biomarkers in the management of community-acquired pneumonia (CAP). Biomarkers have received increasing attention in the management of LRTIs 18. They may help in identifying bacterial aetiology in exacerbations of COPD 19 and in adequately staging severity and prognosis in CAP 18. Krueger et al. 20 presented a communication investigating the predictive value of pro-atrial natriuretic peptide (pro-ANP) and pro-vasopressin (pro-AVP) on short- and long-term survival in 1,740 patients with CAP. In multivariate Cox's proportional hazards regression analyses adjusted for comorbidity and pneumonia severity, pro-ANP and pro-AVP were independent and the strongest predictors of 28- and 180-day survival 20. In a second communication from the same group, the value of copeptin in the evaluation of the severity and prognosis of CAP was investigated using patients from the German Competence Network for Community-Acquired Pneumonia (CAPNETZ). Their results showed that copeptin levels were higher in patients with more severe CAP, but were also higher in patients without antibiotic pretreatment than in those with antibiotic pretreatment, and, therefore, antibiotic pretreatment has to be taken into account for the correct interpretation of copeptin levels in CAP 21.

The third oral session was dedicated to new findings in exacerbations of COPD. Interestingly, pro-ANP, the same marker studied as a prognostic marker in CAP by Krueger et al. 20, was also evaluated as a prognostic factor in patients hospitalised for exacerbation of COPD by Bernasconi et al. 22. They followed-up a group of 167 patients for 2 yrs following discharge for an exacerbation episode, and measured pro-ANP at admission and after 14 days and 6 months. The results showed that pro-ANP levels were higher on admission compared with during recovery and the stable state; additionally, pro-ANP and arterial carbon dioxide tension were independent predictors of mortality on multivariate analysis. The relationship between the pathogen and the host in the bronchial mucosa of COPD is complex, and the mechanisms explaining persistence and colonisation, and the development of exacerbations are still under investigation 23. Desai et al. 24 evaluated the mechanisms explaining the persistence of Streptococcus pneumoniae in relation to specific antibiotics used during exacerbations in a group of 526 patients with isolation of this microorganism. In 94 of these patients, S. pneumoniae was also isolated from sputum at the end of treatment, 77 (82%) of the persistent strains being the same as the initial strain. Moreover, there was a trend for treatment with a β-lactam to be associated more often with strain replacement than that with a ketolide or macrolide. The impact of colonisation by Haemophilus influenzae in patients with COPD was analysed in an abstract presented by Marin-Tapia et al. 25. They investigated 175 stable COPD patients and were able to isolate 71 potentially pathogenic microorganisms (PPMs) from 62 (35%) patients, with H. influenzae being the most prevalent PPM identified. Besides the association of tobacco smoking with a higher prevalence of colonisation, patients carrying PPMs in bronchial secretions also presented with poorer health status as measured by the St George's Respiratory Questionnaire, indicating the relevance of bronchial colonisation in the general well-being of patients. Although sputum is the most readily available sample for microbiological testing, it is subject to the possibility of false-negative or false-positive results due to oropharyngeal contamination 26. In order to avoid these problems, the sampling of lower airways using bronchoscopic techniques may provide a clearer picture regarding the presence of PPMs and associated inflammation in this setting 27. Nesterovich and Bukreeva 28 presented a study on 46 exacerbated COPD patients undergoing bronchoscopy and bronchial brush biopsy sampling. They isolated an infective agent in 36 (78%) cases, 26 with a single pathogen and 10 with mixed infections. Interestingly, their results demonstrated that the bronchial epithelium structure changed according to the type of causative agent, in terms of both cytology and the investigated inflammatory markers. The different inflammatory pattern associated with bacterial and viral aetiology has been observed in severe patients admitted for an exacerbation 29, but the differences in patterns of bronchial damage between intracellular and extracellular pathogens is an interesting finding that may have therapeutic implications or may explain bacterial persistence and residual colonisation following treatment of an acute episode.

LUNG TUBERCULOSIS

During the period 2007–2009, the activities of the Tuberculosis Group within the ERS Respiratory Infections Assembly have been largely influenced by the activities of TBNET, a network of clinical and allied scientists who have joined together in Europe to run multicentric collaborative research projects. The collaboration of TBNET with the ERS as a clinical research collaboration has been very productive, permitting TBNET to operate under the umbrella of the largest respiratory diseases society at the global level, and offering the opportunity to the ERS to be on the front line in the fight against TB, with the publication of original works and reviews on hot topics, such as drug-resistant TB and new diagnostics for TB infection and disease. Furthermore, ongoing multicentric studies are now presented in the scientific sessions on TB during the congress, also increasing the interest and participation of colleagues from overseas. The congress in Vienna was characterised by the high quality of the presentations and posters selected for the scientific sessions; compared to the previous congresses in Berlin (Germany) and Stockholm (Sweden), more stringent and careful selection from the abstracts submitted led to a reduced number of scientific sessions, compensated for by the relevance of the studies presented. Indeed, the acceptance rate decreased from 85.4% (336 out of 397) in 2007 to 78.8% (360 out of 457) in 2008 and 63.6% (255 out of 401) in 2009. In Vienna, the 14 sessions (two oral, eight poster and four E-poster sessions) addressed the most important topics in the field of epidemiology, control, clinical aspects and basic research of TB, with a special focus on the threat represented by MDR- and XDR-TB and on the use of interferon-γ release assays (IGRAs). These latter aspects were the topics covered by the first oral session, where the selected abstracts focused on the new perspectives opened by IGRAs in the diagnosis of TB infection, especially recent versus latent, and the diagnosis of active TB disease. Interesting data were presented on the possibility of differentiating between recent and remote/treated latent TB infection based on the expression of interleukin-2 coupled with interferon-γ 30. Addressing this question, Goletti et al. 31 presented a modified whole-blood assay based on T-cell stimulation with antigens selectively expressed by Mycobacterium tuberculosis in the latency phase. The results of this study show that subjects with remote latent TB infection present a significantly higher interferon-γ response to the antigen Rv2628 than do subjects with recent or active infection. Regarding the use of IGRAs for the diagnosis of active TB, the results of a TBNET multicentric European study presented by Ruhwald et al. 32 reported that an interferon-γ-inducible protein 10-based whole-blood assay showed improved accuracy compared to the respective IGRA. Jafari et al. 33 also presented the final results of a large collaborative multicentric study on the diagnosis of active TB with an enzyme-linked immunospot technique performed on bronchoalveolar lavage fluid cells from sputum-smear-negative pulmonary TB suspects, reporting an extraordinarily high sensitivity and specificity of the method and offering a powerful, fast and relatively simple tool for this challenging diagnosis of the disease.

The second oral session was focused on drug-resistant TB, and especially on MDR- and XDR-TB. In the last year, important studies were published, defining the potential role for moxifloxacin in the standard treatment of TB, to replace ethambutol 34, 35, as well as that of the diarylquinoline TMC207, a very promising new compound tested in phase-II studies 36.

An analysis on determinants of MDR-TB in Germany, Italy, Estonia, Russia and Romania showed that homeless status and HIV infection are strong independent risk factors for the disease, highlighting the need for interventions in these particular groups 37.

Reports from India 38, Turkey 39 and Philippines 40 described how treatment outcomes of MDR-TB patients show a relevant inter-country variation, being improved by the rational use of second-line drugs. These studies confirm once more that MDR-TB can be treated successfully when appropriate control programmes and adequate resources are put in place. Conversely, a study from South Africa described the poor treatment outcomes achieved in XDR-TB cases (regardless of HIV status) 41, a result quite different from that recently reported in Peru 42.

The need for alternative strategies in the treatment of MDR-/XDR-TB was also reflected by the increasing numbers of reports regarding surgical and endoscopic treatment of the disease. In this context, particularly interesting was an abstract reporting the use of endobronchial valves determining atelectasis of cavities caused by XDR-TB 43. Despite the limited number of observations available, this relatively noninvasive method may offer a real alternative to surgical resection or pneumothorax.

Eight thematic poster sessions addressed various important topics. The first session was dedicated to extrapulmonary TB, diseases caused by nontuberculous mycobacteria (NTM) and other emerging pathogens. Eight abstracts were dedicated to NTM, in both immunocompromised and competent hosts, reflecting the increasing number of cases recorded in Europe, and the improved sensitivity of chest physicians to the problem. An interesting nation-based study from Denmark 44 showed that worse prognosis of the disease was associated with isolation of M. xenopi (hazard ratio 1.34; 95% confidence interval 0.87–2.06, compared with M. avium), the presence of comorbid conditions (3.1; 2.3–4.1) and age of >65 yrs (9.2; 5.0–16.9). The difficulties in managing these patients and very high rate of treatment failure/relapse were also highlighted by the follow-up results in two cohorts of patients from Japan 45 and South Korea 46. A case report of rhodococcal pneumonia 47 and other case reports about NTM diseases 48 highlighted the severity of these events, which are being reported with increased frequency.

The second session was dedicated to TB in different age groups, and most of the abstracts reported data from paediatric cohorts, reflecting the increasing attention and sensitivity of doctors to a problem that is also often neglected in high-prevalence countries. A report from Tehran (Iran) stressed very clearly the fact that the diagnosis of TB in paediatric subjects is hampered by the reduced sensitivity of the diagnostic tests used in adults 49. A consistent proportion of patients gave negative chest radiography results, all of them having signs of disease on high-resolution computed tomography. It is noteworthy that the same study reported a slightly higher prevalence of the disease among females aged <15 yrs. The difficulties in the management of paediatric cases with unusual presentations were highlighted in two case reports; a group from Germany discussed the opportunity and timing of surgical drainage of abscesses caused by MDR-TB 50, whereas a group from Romania described a case of meningitis with unusual cerebrospinal fluid features 51.

The need to increase the sensitivity of TB diagnosis among children was stressed by a Croatian study reporting a decrease in the number of paediatric cases in a major hospital 52. The authors highlighted the facts that: 1) most of them were family contacts (in ∼80% of cases the index case was one of the parents); and 2) an increasing number of them were diagnosed through implementation of quality contact-tracing procedures.

Another session reflected the increasing importance of another risk group, i.e. patients with immunosuppression induced by anti-tumour necrosis factor-α drugs. Seven out of 20 abstracts in the “Clinical immunology of tuberculosis” session were focused on this issue and on the need to improve pretreatment screening procedures.

As in Berlin, participants in Vienna also had the chance to present and discuss original research studies through electronic sessions, a new methodology the ERS is still evaluating with particular interest.

A total of 80 abstracts were presented in four electronic sessions organised to discuss TB and HIV co-infection, contact-tracing procedures, proof of concepts for new diagnostics, and treatment of MDR- and XDR-TB. During these sessions, interesting cases caused by emerging pathogens, such as M. tilburgii 53 and M. sherisii 54, were reported and discussed, as well as the novelty and limits of new diagnostic techniques, such as IGRAs, in patients with advanced HIV co-infection 55.

The session dedicated to contact-tracing procedures reported data from different settings and targeted populations, highlighting the improvements and operational advantages related to the use of new blood tests, especially among children 56 and subjects with confounding factors, such as healthcare workers 57. Preliminary results showed a high negative predictive value for serum procalcitonin levels in the differential diagnosis between pulmonary TB and other pulmonary infections 58.

CONCLUSIONS

Interesting contributions towards a better understanding of pathogenesis, diagnosis, treatment, prognostic factors and new diagnostic techniques for bacterial and viral infections were presented at the Vienna Congress.

Similarly, the contribution of the studies presented in Vienna permitted a clearer understanding to be obtained regarding the use of IGRAs in the diagnosis of latent and active TB, and shedding of further light on MDR- and XDR-TB diagnosis, clinical management and control.

Owing to the active involvement of several members of the Respiratory Infection Assembly in various high-profile projects 5–7, quality answers to the questions pending relating to the management of community-acquired LRTI and TB are expected in the near future.

Acknowledgments

The authors wish to thank R. Centis (World Health Organization Collaborating Centre for Tuberculosis and Lung Diseases, S. Maugeri Foundation, Care and Research Institute, Tradate, Italy) for support through the editorial process of this manuscript.

Footnotes

  • Statement of Interest

    None declared.

  • Received April 8, 2010.
  • Accepted April 22, 2010.
  • ©2010 ERS

REFERENCES

  1. ↵
    1. Woodhead M,
    2. Blasi F,
    3. Ewig S,
    4. et al
    . Guidelines for the management of adult lower respiratory tract infections. Eur Respir J 2005; 26: 1138–1180.
    OpenUrlAbstract/FREE Full Text
  2. ↵
    World Health Organization, Global Tuberculosis Control 2009: Epidemiology. Strategy. Financing: WHO Report 2009. Geneva, World Health Organization, 2009
  3. ↵
    World Health Organization, Multidrug and Extensively Drug-Resistant TB (M/XDR-TB): 2010 Global Report on Surveillance and Response. Geneva, World Health Organization, 2010
  4. ↵
    1. Sotgiu G,
    2. Ferrara G,
    3. Matteelli A,
    4. et al
    . Epidemiology and clinical management of XDR-TB: a systematic review by TBNET. Eur Respir J 2009; 33: 871–881.
    OpenUrlAbstract/FREE Full Text
  5. ↵
    Genomics to combat Resistance against Antibiotics in Community-acquired LRTI in Europe. Genomics to combat Resistance against Antibiotics in Community-acquired LRTI in Europe. www.grace-lrti.org Date last updated: April 8, 2010. Date last accessed: April 8, 2010.
  6. ↵
    TB PAN-NET. European Network for Study and Clinical Management of TB Drug Resistance. www.tbpannet.eu Date last updated: April 8, 2010. Date last accessed: April 8, 2010.
  7. ↵
    1. Sotgiu G,
    2. Centis R,
    3. D'Ambrosio L,
    4. et al
    . Development of a standardised tool to survey MDR-/XDR-TB case management in Europe. Eur Respir J 2010; 36: 208–211.
    OpenUrlFREE Full Text
  8. ↵
    1. Ewig S,
    2. Soler N,
    3. Gonzalez J,
    4. et al
    . Evaluation of antimicrobial treatment in mechanically ventilated patients with severe chronic obstructive pulmonary disease exacerbations. Crit Care Med 2000; 28: 692–697.
    OpenUrlCrossRefPubMedWeb of Science
  9. ↵
    1. Jiang H,
    2. Li Z
    . Effect of biofilm on induced β-lactamase production in Pseudomonas aeruginosa with different genotype. Eur Respir J 2009; 34 Suppl. 53:231s–
    OpenUrlCrossRef
  10. ↵
    1. Eller J,
    2. Ede A,
    3. Schaberg T,
    4. et al
    . Infective exacerbations of chronic bronchitis: relation between bacteriologic etiology and lung function. Chest 1998; 113: 1542–1548.
    OpenUrlCrossRefPubMedWeb of Science
  11. ↵
    1. Miravitlles M,
    2. Espinosa C,
    3. Fernandez-Laso E,
    4. et al
    . Relationship between bacterial flora in sputum and functional impairment in patients with acute exacerbations of COPD. Chest 1999; 116: 40–46.
    OpenUrlCrossRefPubMedWeb of Science
    1. Lode H,
    2. Allewelt M,
    3. Balk S,
    4. et al
    . A prediction model for bacterial etiology in acute exacerbations of COPD. Infection 2007; 35: 143–149.
    OpenUrlCrossRefPubMedWeb of Science
  12. ↵
    1. Monsó E,
    2. García-Aymerich J,
    3. Soler N,
    4. et al
    . Bacterial infection in exacerbated COPD with changes in sputum characteristics. Epidemiol Infect 2003; 131: 799–804.
    OpenUrlCrossRefPubMed
  13. ↵
    1. Soler N,
    2. Torres A,
    3. Ewig S,
    4. et al
    . Bronchial microbial patterns in severe exacerbations of chronic obstructive pulmonary disease (COPD) requiring mechanical ventilation. Am J Respir Crit Care Med 1998; 157: 1498–1505.
    OpenUrlCrossRefPubMedWeb of Science
  14. ↵
    1. Murphy TF,
    2. Brauer AL,
    3. Eschberger K,
    4. et al
    . Pseudomonas aeruginosa in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2008; 177: 853–860.
    OpenUrlCrossRefPubMedWeb of Science
  15. ↵
    1. O'Donnell A,
    2. Swarnakar R,
    3. Yashina L,
    4. et al
    . A placebo-controlled study of liposomal amikacin for inhalation nebulized once daily in the treatment of bronchiectasis patients with chronic Pseudomonas aeruginosa lung infection. Eur Respir J 2009; 34 Suppl. 53:231s.
    OpenUrlCrossRef
  16. ↵
    1. Bilton D,
    2. DeSoyza A,
    3. Haworth C,
    4. et al
    . Inhaled liposomal ciprofloxacin hydrochloride significantly reduces sputum Pseudomonas aeruginosa density in non-CF bronchiectasis. Eur Respir J 2009; 34 Suppl. 53:231s–
    OpenUrlCrossRef
  17. ↵
    1. Christ-Crain M,
    2. Müller B
    . Biomarkers in respiratory tract infections: diagnostic guides to antibiotic prescription, prognostic markers and mediators. Eur Respir J 2007; 30: 556–573.
    OpenUrlAbstract/FREE Full Text
  18. ↵
    1. Stolz D,
    2. Christ-Crain M,
    3. Bingisser R
    . Antibiotic treatment of exacerbations of COPD: a randomised, controlled trial comparing procalcitonin-guidance with standard therapy. Chest 2007; 131: 9–19.
    OpenUrlCrossRefPubMedWeb of Science
  19. ↵
    1. Krueger S,
    2. Ewig S,
    3. Kunde J,
    4. et al
    . Pro-atrial natriuretic peptide and pro-vasopressin to predict short- and long-term survival in community-acquired pneumonia. Eur Respir J 2009; 34 Suppl. 53:296s.
    OpenUrl
  20. ↵
    1. Krueger S,
    2. Ewig S,
    3. Kunde J,
    4. et al
    . Pro-vasopressin (copeptin) in patients with community-acquired pneumonia – influence of antibiotic pre-treatment; results from the German competence network CAPNETZ. Eur Respir J 2009; 34 Suppl. 53:296s.
    OpenUrl
  21. ↵
    1. Bernasconi M,
    2. Christ-Crain M,
    3. Müller C,
    4. et al
    . MR-proANP predicts 2-year survival in patients admitted for acute exacerbation of COPD. Eur Respir J 2009; 34 Suppl. 53:748s–749s.
    OpenUrl
  22. ↵
    1. Sethi S,
    2. Evans N,
    3. Grant BJ,
    4. et al
    . New strains of bacteria and exacerbations of chronic obstructive pulmonary disease. N Engl J Med 2002; 347: 465–471.
    OpenUrlCrossRefPubMedWeb of Science
  23. ↵
    1. Desai H,
    2. Johnson A,
    3. Murphy T,
    4. et al
    . Mechanisms of persistence of Streptococcus pneumoniae following treatment of acute exacerbation of chronic bronchitis. Eur Respir J 2009; 34 Suppl. 53:749s–
    OpenUrlCrossRef
  24. ↵
    1. Marín-Tapia A,
    2. García-Aymerich J,
    3. Monsó E,
    4. et al
    . Effects of colonisation by Haemophilus influenzae in COPD stable patients. Eur Respir J 2009; 34 Suppl. 53:749s–750s.
    OpenUrlCrossRef
  25. ↵
    1. Murphy TF,
    2. Brauer AL,
    3. Schiffmacher T,
    4. et al
    . Persistent colonization by Haemophilus influenzae in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2004; 170: 266–272.
    OpenUrlCrossRefPubMedWeb of Science
  26. ↵
    1. Soler N,
    2. Agustí C,
    3. Angrill J,
    4. et al
    . Bronchoscopic validation of the significance of sputum purulence in severe exacerbations of chronic obstructive pulmonary disease. Thorax 2007; 62: 29–35.
    OpenUrlAbstract/FREE Full Text
  27. ↵
    1. Nesterovich S,
    2. Bukreeva E
    . Peculiarities of brush-biopsies of bronchial mucosa at different aetiology of COPD exacerbations. Eur Respir J 2009; 34 Suppl. 53:412s.
    OpenUrl
  28. ↵
    1. Papi A,
    2. Bellettato CM,
    3. Braccioni F,
    4. et al
    . Infections and airway inflammation in chronic obstructive pulmonary disease severe exacerbations. Am J Respir Crit Care Med 2006; 173: 1114–1121.
    OpenUrlCrossRefPubMedWeb of Science
  29. ↵
    1. Biselli R,
    2. Mariotti S,
    3. Sargentini V,
    4. et al
    . Detection of IL-2 in addition to IFN-γ discriminates active tuberculosis patients, latently infected individuals and controls. Clin Microbiol Infect 2009; [Epub ahead of print PMID: 19886902]
  30. ↵
    1. Goletti D,
    2. Butera O,
    3. Vanini V,
    4. et al
    . Response to Rv2628 latency antigen associates with cured tuberculosis and remote infection. Eur Respir J 2010; 36: 135–142.
    OpenUrlAbstract/FREE Full Text
  31. ↵
    1. Ruhwald M,
    2. Bodmer T,
    3. Maier C,
    4. et al
    . Evaluating the potential of IP-10 and MCP-2 as biomarkers for the diagnosis of tuberculosis. Eur Respir J 2008; 32: 1607–1615.
    OpenUrlAbstract/FREE Full Text
  32. ↵
    1. Jafari C,
    2. Thijsen S,
    3. Sotgiu G,
    4. et al
    . Bronchoalveolar lavage enzyme-linked immunospot for a rapid diagnosis of tuberculosis. A Tuberculosis Network European Trialsgroup study. Am J Respir Crit Care Med 2009; 180: 666–673.
    OpenUrlCrossRefPubMedWeb of Science
  33. ↵
    1. Dorman SE,
    2. Johnson JL,
    3. Goldberg S,
    4. et al
    . Substitution of moxifloxacin for isoniazid during intensive phase treatment of pulmonary tuberculosis. Am J Respir Crit Care Med 2009; 180: 273–280.
    OpenUrlCrossRefPubMedWeb of Science
  34. ↵
    1. Conde MB,
    2. Efron A,
    3. Loredo C,
    4. et al
    . Moxifloxacin versus ethambutol in the initial treatment of tuberculosis: a double-blind, randomised, controlled phase II trial. Lancet 2009; 373: 1183–1189.
    OpenUrlCrossRefPubMedWeb of Science
  35. ↵
    1. Diacon AH,
    2. Pym A,
    3. Grobusch M,
    4. et al
    . The diarylquinoline TMC207 for multidrug-resistant tuberculosis. N Engl J Med 2009; 360: 2397–2405.
    OpenUrlCrossRefPubMedWeb of Science
  36. ↵
    1. Sotgiu G,
    2. Sorete-Arbore A,
    3. Kliimann K,
    4. et al
    . Social determinants of MDR-TB in Europe: a multi-centre TBNET study. Eur Respir J 2009; 34 Suppl. 53:786s.
    OpenUrl
  37. ↵
    1. Prasad BNBM,
    2. Rai SP,
    3. Falleiro JJ,
    4. et al
    . Prevalence and treatment outcome of drug resistant pulmonary tuberculosis in HIV negative cases – experience from a tuberculosis treatment center in India. Eur Respir J 2009; 34 Suppl. 53:786s–787s.
    OpenUrl
  38. ↵
    1. Saygi A,
    2. Sungun F,
    3. Ekinci T,
    4. et al
    . Treatment outcome in multidrug resistant tuberculosis cases at our clinic between 1996–2008. Eur Respir J 2009; 34 Suppl. 53:787s–
    OpenUrlCrossRef
  39. ↵
    1. Legaspi MV
    . A two-year post-treatment follow-up of multi-drug resistant tuberculosis cases who completed a programmatic MDR-TB management at the lung center of the Philippines: a preliminary report. Eur Respir J 2009; 34 Suppl. 53:787s.
    OpenUrlCrossRef
  40. ↵
    1. Dheda K,
    2. Shean K,
    3. Badri M
    . Extensively drug-resistant tuberculosis. N Engl J Med 2008; 359: 2390–
    OpenUrlCrossRefPubMedWeb of Science
  41. ↵
    1. Mitnick CD,
    2. Shin SS,
    3. Seung KJ,
    4. et al
    . Comprehensive treatment of extensively drug-resistant tuberculosis. N Engl J Med 2008; 359: 563–574.
    OpenUrlCrossRefPubMedWeb of Science
  42. ↵
    1. Lovacheva O,
    2. Sivokozov I,
    3. Bagdasaryan T,
    4. et al
    . Local artificial atelectasis in treatment of end-stage XDR cavitary tuberculosis. Eur Respir J 2009; 34 Suppl. 53:787s.
    OpenUrlCrossRef
  43. ↵
    1. Andrejak C,
    2. Thomsen V,
    3. Johansen I,
    4. et al
    . The prognosis of patients colonized and infected with pulmonary nontuberculous mycobacteria in Denmark, 1997–2007: a nationwide population-based study. Eur Respir J 2009; 34 Suppl. 53:435s.
    OpenUrl
  44. ↵
    1. Kobashi Y,
    2. Mouri K,
    3. Obase Y,
    4. et al
    . Long-term observation of pulmonary Mycobacterium avium complex disease treated with chemotherapy following the guidelines for treatment. Eur Respir J 2009; 34 Suppl. 53:435s.
    OpenUrl
  45. ↵
    1. Sim YS,
    2. Park HY,
    3. Kwon OJ,
    4. et al
    . Treatment outcome and prognostic factor in patients with Mycobacterium avium complex pulmonary disease. Eur Respir J 2009; 34 Suppl. 53:436s–
    OpenUrlCrossRef
  46. ↵
    1. Greinert H,
    2. Hörster R,
    3. Hoffmann C,
    4. et al
    . Successful treatment of rhodococcal pneumonia in advanced HIV-infection. Eur Respir J 2009; 34 Suppl. 53:436s.
    OpenUrlCrossRef
  47. ↵
    1. Shah A,
    2. Strickland N,
    3. Thomas C,
    4. et al
    . Characterisation of patients with multiple isolates of different species of non-tuberculous mycobacteria: a new phenomenon?. Eur Respir J 2009; 34 Suppl. 53:435s.
    OpenUrl
  48. ↵
    1. Khalilzadeh S,
    2. Baghaie N,
    3. Bloorsaz MR,
    4. et al
    . Bacteriological evaluation for diagnosis of tuberculosis in children. Eur Respir J 2009; 34 Suppl. 53:438s.
    OpenUrl
  49. ↵
    1. Brinkmann F,
    2. Schwerk N,
    3. Gappa M,
    4. et al
    . Psoas abscesses in a child with multidrug resistant tuberculosis: is surgical drainage indicated?. Eur Respir J 2009; 34 Suppl. 53:440s.
    OpenUrl
  50. ↵
    1. Dobrota L,
    2. Neamtu M-L,
    3. Neamtu B,
    4. et al
    . P2492 chronic meningitis: a rare form of onset of tuberculosis infection in infants. Eur Respir J 2009; 34 Suppl. 53:440s.
    OpenUrl
  51. ↵
    1. Pavlov N,
    2. Dragisic-Ivulic S,
    3. Pavlov V
    . Epidemiologic trends in children with tuberculosis (1999–2009). Eur Respir J 2009; 34 Suppl. 53:439s–440s.
    OpenUrl
  52. ↵
    1. Eker B,
    2. Welling J,
    3. Greinert U,
    4. et al
    . Mycobacterium tilburgii infection in an HIV-seropositive host. Eur Respir J 2009; 34 Suppl. 53:575s.
    OpenUrl
  53. ↵
    1. Guenther G,
    2. Uhrig A,
    3. Lange C,
    4. et al
    . High-frequency oscillatory ventilation (HFOV) effectively removed CO2 in AIDS related severe Mycobacterium sherisii infection with acute respiratory distress syndrome (ARDS). Eur Respir J 2009; 34 Suppl. 53:575s.
    OpenUrl
  54. ↵
    1. Leidl L,
    2. Mayanja-Kizza H,
    3. Sotgiu G,
    4. et al
    . Relationship of interferon-gamma release assay results and tuberculin skin test results to numbers of circulating CD4 T-cells in HIV infection. Eur Respir J 2009; 34 Suppl. 53:573s.
    OpenUrl
  55. ↵
    1. Diez N,
    2. Latorre I,
    3. Giner E,
    4. et al
    . IFN-γ T cell response in the diagnosis of latent tuberculosis infection in children with a positive tuberculin skin test. Eur Respir J 2009; 34 Suppl. 53:65s.
    OpenUrl
  56. ↵
    1. Losi M,
    2. Corona GL,
    3. Del Giovane C,
    4. et al
    . Using QuantiFERON-TB gold in-tube in contact tracing procedures. Eur Respir J 2009; 34 Suppl. 53:66s.
    OpenUrl
  57. ↵
    1. Strassburg A,
    2. Guenther G,
    3. Sahly H,
    4. et al
    . Negative predictive value of serum-procalcitonin (PCT) for active pulmonary tuberculosis (pTB). Eur Respir J 2009; 34 Suppl. 53:284s.
    OpenUrlCrossRef
PreviousNext
Back to top
View this article with LENS
Vol 36 Issue 3 Table of Contents
European Respiratory Journal: 36 (3)
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
TB or not TB: update from the ERS Respiratory Infection Assembly 10
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Print
Alerts
Sign In to Email Alerts with your Email Address
Citation Tools
TB or not TB: update from the ERS Respiratory Infection Assembly 10
M. Miravitlles, G. Ferrara, C. Lange, G. Dimopoulos, G. Rohde, F. Blasi, G.B. Migliori
European Respiratory Journal Sep 2010, 36 (3) 665-670; DOI: 10.1183/09031936.00054410

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
TB or not TB: update from the ERS Respiratory Infection Assembly 10
M. Miravitlles, G. Ferrara, C. Lange, G. Dimopoulos, G. Rohde, F. Blasi, G.B. Migliori
European Respiratory Journal Sep 2010, 36 (3) 665-670; DOI: 10.1183/09031936.00054410
del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo
Full Text (PDF)

Jump To

  • Article
    • Abstract
    • RESPIRATORY INFECTIONS
    • LUNG TUBERCULOSIS
    • CONCLUSIONS
    • Acknowledgments
    • Footnotes
    • REFERENCES
  • Info & Metrics
  • PDF

Subjects

  • Respiratory infections and tuberculosis
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

  • Paediatrics in Barcelona
  • ERS Clinical Assembly update
  • paediatrics in vienna
Show more Scientific Assembly Update

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About the ERJ

  • Journal information
  • Editorial board
  • Reviewers
  • CME
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Submit a manuscript
  • ERS author centre

For readers

  • Alerts
  • Subjects
  • Podcasts
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN:  0903-1936
Online ISSN: 1399-3003

Copyright © 2021 by the European Respiratory Society